NO20014537L - AKT-nukleinsyrer, -polypeptider og anvendelse av disse - Google Patents

AKT-nukleinsyrer, -polypeptider og anvendelse av disse

Info

Publication number
NO20014537L
NO20014537L NO20014537A NO20014537A NO20014537L NO 20014537 L NO20014537 L NO 20014537L NO 20014537 A NO20014537 A NO 20014537A NO 20014537 A NO20014537 A NO 20014537A NO 20014537 L NO20014537 L NO 20014537L
Authority
NO
Norway
Prior art keywords
polypeptides
nucleic acids
akt3
akt nucleic
relates
Prior art date
Application number
NO20014537A
Other languages
English (en)
Other versions
NO20014537D0 (no
Inventor
Kun Guo
Marco F Pagnoni
Kenneth L Clark
Yuri D Ivashchenko
Original Assignee
Aventis Pharm Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharm Prod Inc filed Critical Aventis Pharm Prod Inc
Publication of NO20014537D0 publication Critical patent/NO20014537D0/no
Publication of NO20014537L publication Critical patent/NO20014537L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1205—Phosphotransferases with an alcohol group as acceptor (2.7.1), e.g. protein kinases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/022—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from an adenovirus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/027—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a retrovirus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/028—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a herpesvirus

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Microbiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Transplantation (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Vascular Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Saccharide Compounds (AREA)
NO20014537A 1999-03-19 2001-09-18 AKT-nukleinsyrer, -polypeptider og anvendelse av disse NO20014537L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US12510899P 1999-03-19 1999-03-19
PCT/US2000/006574 WO2000056866A2 (en) 1999-03-19 2000-03-14 Akt-3 nucleic acids, polypeptides, and uses thereof

Publications (2)

Publication Number Publication Date
NO20014537D0 NO20014537D0 (no) 2001-09-18
NO20014537L true NO20014537L (no) 2001-10-31

Family

ID=22418217

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20014537A NO20014537L (no) 1999-03-19 2001-09-18 AKT-nukleinsyrer, -polypeptider og anvendelse av disse

Country Status (18)

Country Link
EP (1) EP1144600B1 (no)
JP (1) JP4237945B2 (no)
KR (1) KR100700908B1 (no)
AT (1) ATE402995T1 (no)
AU (1) AU782448B2 (no)
BR (1) BR0009170A (no)
CA (1) CA2343074C (no)
CY (1) CY1108459T1 (no)
DE (1) DE60039677D1 (no)
DK (1) DK1144600T3 (no)
ES (1) ES2310515T3 (no)
HK (1) HK1041288B (no)
IL (4) IL145514A0 (no)
NO (1) NO20014537L (no)
PT (1) PT1144600E (no)
SI (1) SI1144600T1 (no)
WO (1) WO2000056866A2 (no)
ZA (1) ZA200108414B (no)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6881555B2 (en) 1999-03-19 2005-04-19 Aventis Pharmaceuticals Inc. AKT nucleic acids, polypeptides, and uses thereof
EP1178722A4 (en) * 1999-04-16 2003-03-05 Univ Yale ENOS MUTATIONS FOR GENTHERAPY AND THERAPEUTIC SCREENING
JP2003530818A (ja) * 1999-06-11 2003-10-21 アベンティス・ファーマスーティカルズ・インコーポレイテツド セリン／トレオニンプロテインキナーゼＡｋｔによる血管内皮成長因子（ＶＥＧＦ）の導入
WO2003063905A1 (en) * 2002-01-31 2003-08-07 Center For Advanced Science And Technology Incubation, Ltd. Preventives or remedies for immunological diseases
US20060051407A1 (en) * 2003-06-27 2006-03-09 Yoram Richter Method of treating ischemia-reperfusion injury
US10517883B2 (en) 2003-06-27 2019-12-31 Zuli Holdings Ltd. Method of treating acute myocardial infarction
US20070167386A1 (en) * 2003-07-28 2007-07-19 Osaka Industrial Promotion Organization Remedy for cardiac failure containing ask1 inhibitor as active ingredient and method for screening the same
EP2304439A4 (en) 2008-05-29 2012-07-04 Nuclea Biotechnologies Llc ANTI-phospho-AKT ANTIBODY
TWI491606B (zh) 2009-07-13 2015-07-11 Gilead Sciences Inc 調節細胞凋亡信號之激酶的抑制劑
AU2011272782B2 (en) 2010-07-02 2014-11-27 Gilead Sciences, Inc. Apoptosis signal-regulating kinase inhibitors
UY34573A (es) 2012-01-27 2013-06-28 Gilead Sciences Inc Inhibidor de la quinasa que regula la señal de la apoptosis
US9993427B2 (en) 2013-03-14 2018-06-12 Biorest Ltd. Liposome formulation and manufacture
SG11201701723XA (en) 2014-09-24 2017-04-27 Gilead Sciences Inc Methods of treating liver disease
MA41252A (fr) 2014-12-23 2017-10-31 Gilead Sciences Inc Formes solides d'un inhibiteur d'ask 1
WO2016106384A1 (en) 2014-12-23 2016-06-30 Gilead Sciences, Inc. Processes for preparing ask1 inhibitors
JP7637060B2 (ja) * 2019-03-04 2025-02-27 ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア Ａｋｔ経路を標的とする神経保護遺伝子療法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH08109197A (ja) * 1994-10-07 1996-04-30 Sumitomo Electric Ind Ltd 白血病腫瘍拒絶抗原ペプチド
EP0862622B1 (en) * 1995-11-16 2004-08-18 Novartis AG Method of screening for RAC protein kinase interacting compounds
US5958773A (en) * 1998-12-17 1999-09-28 Isis Pharmaceuticals Inc. Antisense modulation of AKT-1 expression
GB9828375D0 (en) * 1998-12-22 1999-02-17 Janssen Pharmaceutica Nv Human akt-3
US6043090A (en) * 1999-03-23 2000-03-28 Isis Pharmaceuticals Inc. Antisense inhibition of human Akt-2 expression
WO2000058473A2 (en) * 1999-03-31 2000-10-05 Curagen Corporation Nucleic acids including open reading frames encoding polypeptides; 'orfx'
JP2003530818A (ja) * 1999-06-11 2003-10-21 アベンティス・ファーマスーティカルズ・インコーポレイテツド セリン／トレオニンプロテインキナーゼＡｋｔによる血管内皮成長因子（ＶＥＧＦ）の導入

Also Published As

Publication number Publication date
PT1144600E (pt) 2008-10-10
ZA200108414B (en) 2003-03-26
SI1144600T1 (sl) 2008-12-31
HK1041288A1 (en) 2002-07-05
DK1144600T3 (da) 2008-11-24
NO20014537D0 (no) 2001-09-18
ES2310515T3 (es) 2009-01-16
AU3880200A (en) 2000-10-09
CA2343074C (en) 2010-09-21
BR0009170A (pt) 2002-04-30
IL145514A0 (en) 2002-06-30
CY1108459T1 (el) 2013-09-04
KR20020011972A (ko) 2002-02-09
IL145514A (en) 2010-05-17
AU782448B2 (en) 2005-07-28
EP1144600B1 (en) 2008-07-30
ATE402995T1 (de) 2008-08-15
WO2000056866A2 (en) 2000-09-28
JP2002539781A (ja) 2002-11-26
HK1041288B (en) 2008-11-07
JP4237945B2 (ja) 2009-03-11
CA2343074A1 (en) 2000-09-28
WO2000056866A9 (en) 2002-08-29
WO2000056866A3 (en) 2001-02-15
KR100700908B1 (ko) 2007-03-29
IL190270A (en) 2012-12-31
DE60039677D1 (de) 2008-09-11
EP1144600A2 (en) 2001-10-17
IL141984A0 (en) 2002-03-10

Similar Documents

Publication Publication Date Title
CY1108459T1 (el) Ακτ-3 νουκλεϊκα οξεα, πολυπεπτιδια, και χρησεις αυτων
HUP0003533A2 (hu) Interleukin-18-at kötő fehérjék, előállításuk és alkalmazásuk
BR9811956B1 (pt) naftiridinonas e composição farmacêutica compreendendo as mesmas.
BR0315688A (pt) Compostos, composições farmacêuticas e seus usos no tratamento ou prevenção de doenças ou condições de proliferação celular metabólicas
DK0910647T3 (da) Human DNase i hyperaktive varianter
ATE476495T1 (de) Bazillus thuringiensis und dessen insektizide proteine
DE602004011770D1 (de) Fusionsproteine
DK0750672T3 (da) DNA-sekvenser for matrix-metalproteaser, deres tilvejebringelse og anvendelse
CA2388910A1 (en) Antimicrobial activity of the first cationic cluster of human lactoferrin
GB0418388D0 (en) Cell therapy
BR0212070A (pt) ácidos nucléicos e polipeptìdeos bv8 com atividade mitogênica
IL149416A0 (en) Human enzymes of the metalloprotease family
WO2002014369A3 (en) Human kininogen d5 domain polypeptides and their use
UA84831C2 (ru) Производные фактора коагуляции vii
ZA95968B (en) Interferon alpha/beta binding protein its preparation and use
WO2022248651A3 (en) Inhibitory nucleic acids for factor h family proteins
BR0108187A (pt) Moléculas trade e usos relacionados com as mesmas
HUP0300813A2 (hu) Gének, fehérjék és alkalmazásuk
BR9407357A (pt) Novos tripeptideos utilizáveis em terapia cns e imune
IL174645A0 (en) MODIFIED cDNA FOR HIGH EXPRESSION LEVELS OF FACTOR VIII AND ITS DERIVATIVES
AU2002246455A1 (en) Fusion proteins for specific treatment of cancer and auto-immune diseases
DE602005021159D1 (de) Bakteriophagen- und prophagen-proteine in der krebsgentherapie
AU2001274088A1 (en) Screening-method for modulators of methyltransferase-dependent chromosome stability
DK0980379T3 (da) Chimære oligonucleotider og deres anvendelse
GB9723824D0 (en) Cytostatic agents